CDY’s midkine antibody shown to accelerate bone fracture healing

Published at Jun 24, 2016, in Biotech

Australian biotechnology company Cellmid Limited (ASX:CDY) has announced that its midkine (MK) antibody has been shown to accelerate the bone healing and formation process.

The study led by Dr Astrid Liedert at the Orthopedic Research and Biomechanics, University Medical Center Ulm, Germany is the first ever in showing CDY’s technology in action, a major milestone for the company.

The results were published in the esteemed British Journal of Pharmacology:

(Haffner-Luntzer M et al, Antagonizing Midkine Accelerates Fracture Healing in Mice by Enhanced Bone Formation in the Fractured Callus. Br J Pharmacol. doi: 10.1111/bph.13503. PMID: 27111560)

The study concluded that “Mdk-Ab treatment may be a potential novel therapeutic strategy to enhance fracture healing in patients with orthopedic complications such as delayed healing or non-union formation.”

The clinically significant results are a step forward for CDY in seeking to address the need in the bone fracture market, where up to 10% of all bone fractures result in delayed bone healing and even-union formation.

This is of great concern in the world’s increasing ageing population, where fractures often take an extended amount of time to heal. Placing great burden on the patient, health care system and care givers, highlighting the need for better therapies such as CDY’s MK antibodies.

Further to these latest promising results, CDY has filed a patent application to secure its IP in the application of its MK antibodies in bone therapy.

Today’s announcement contributes to positive data and promising results already gathered in relation to CDY’s MK antibodies treatment of chronic kidney disease.

MK has been shown to be an important early marker for diagnosing various diseases and is only evident in a disease context. Unlike many other forms of treatment, targeting MK is not expected to harm normal health tissue.

CDY plans to commercialise its MK antibody through wholly owned subsidiary Lyramid Limited, which is dedicated to developing drugs in treating various conditions targeting MK.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn